CRL — Charles River Laboratories Inte

Is CRL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of November 17, 2026

Charles River Laboratories Inte (CRL) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $332.16. The rating moved from Overbought to Neutral on November 13, 2026.

AI analysis

Charles River Laboratories Inte is well positioned to benefit from ongoing pharma/biotech outsourcing and the shift toward specialty biologics and infusion therapies. The firm's diversified service set, backlog characteristics and relationships with large pharma support steady revenue and cash generation, while sector consolidation and large-cap pharma momentum can create additional contract and M&A tailwinds. Near-term performance depends on execution of margin initiatives, integration of any recent investments, and the macro/R&D spending environment. Limited social sentiment data and absent fresh filing detail increase near-term information risk, but the structural growth drivers and defensive characteristics of large-client relationships underpin a favorable multi‑quarter outlook.

Key factors

  • Market-leading CRO and biopharma services platform with diversified revenue across preclinical, discovery and manufacturing services
  • Secular outsourcing trend in pharma/biotech supports steady long-term demand for third-party research and development services
  • Distributor shift to specialty care and expanded adoption of biologics and complex therapies increases addressable service volumes
  • Large-cap pharma strength and consolidation activity can drive incremental contract wins, partnerships and M&A opportunities
  • Relatively stable recurring revenue and long-term customer relationships create predictable cash flow and backlog visibility

Risks

  • Slower R&D spending or macro-driven cutbacks at pharma/biotech customers could compress volumes and utilization
  • Quality-control, regulatory inspection findings or compliance issues could lead to project delays, remediation costs and reputational damage
  • Pricing pressure from competitors and capacity overhang in some service lines could weigh on margin expansion
  • Integration and execution risk from acquisitions or large contracts may temporarily impair operating performance
  • Foreign exchange exposure and cyclical capital markets volatility that can affect smaller biotech clients and deal flow

See today's live rating, score and targets

Members see the live hourly rating for CRL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.